MedTrace Logo

Open Label Extension In Cancer Patients

NCT00830180 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2021-04-05

Study results available
· View outcomes & findings →

Summary

To evaluate the safety and efficacy of anti-NGF AB in cancer patients with pain due to bone metastases who participated in the double-blind Study A4091003 and who wish to receive open-label therapy.

Conditions

Interventions

BIOLOGICAL

Anti-NGF AB

Solution for injection, 10 mg, one injection/8 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-29
Primary Completion
2013-02-14
Completion
2013-02-14

Countries

  • United States
  • Austria
  • Bosnia and Herzegovina
  • Croatia
  • Hungary
  • India
  • Latvia
  • Poland
  • Slovakia
  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00830180 on ClinicalTrials.gov